Literature DB >> 27826047

Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors.

Jikai Liu1, Dawei Li2, Li Cao2, Zhanyu Wang1, Yan Li2, Hainan Liu2, Gang Chen3.   

Abstract

PURPOSE: To investigate the association between preoperative plasma fibrinogen levels and clinicopathological features in patients with bladder urothelial tumors.
METHODS: In this retrospective single-center study, we evaluated preoperative plasma fibrinogen levels in 503 patients newly diagnosed with bladder urothelial tumors between January 2009 and October 2014. All patients received surgical intervention as the primary treatment method. Associations between preoperative plasma fibrinogen levels and clinicopathological parameters were analyzed. Univariate and multivariate logistic regression analyses were performed to identify independent associations.
RESULTS: The mean preoperative fibrinogen level in patients with bladder urothelial carcinoma (BUC) was significantly higher than that in patients with papilloma or papillary urothelial neoplasm of low malignant potential (PUNLMP) (P = 0.004). Additionally, patients with BUC with advanced-stage disease showed elevated plasma fibrinogen levels compared to patients with early-stage disease (high-grade BUC vs. low-grade BUC: P = 0.002; muscle-invasive BUC vs. non-muscle-invasive BUC: P = 0.010). In a multivariate regression model, a plasma fibrinogen level >3.04 g/L was identified to be independently associated with the presence of BUC (hazard ratio [HR] = 1.653, P = 0.047), high-grade BUC (HR = 1.869, P = 0.004), and muscle-invasive BUC (HR = 1.870, P = 0.044).
CONCLUSIONS: Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy as well as advanced-stage carcinoma in patients with bladder urothelial tumors, suggesting that plasma fibrinogen may be a promising diagnostic and prognostic biomarker for bladder tumors.
Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder urothelial tumor; Clinicopathological feature; Plasma fibrinogen

Mesh:

Substances:

Year:  2016        PMID: 27826047     DOI: 10.1016/j.ijsu.2016.11.010

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  6 in total

1.  The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis.

Authors:  Xingxing Tang; Peng Du; Yong Yang
Journal:  Int J Clin Oncol       Date:  2017-07-27       Impact factor: 3.402

2.  Plasma Fibrinogen Predicts the Prognosis of Bladder Cancer Patients After Radical Cystectomy.

Authors:  Shuai Yang; Han Guan; Sheng Wang; Hongliang Wu; Wenyan Sun; Zhijun Chen; Qingwen Li
Journal:  Cancer Manag Res       Date:  2020-09-29       Impact factor: 3.989

3.  Serum Cystatin C Level Is Not a Promising Biomarker for Predicting Clinicopathological Characteristics of Bladder Urothelial Tumors.

Authors:  Hui Wang; Lijian Gao; Cuiyu Meng; Nengwang Yu; Feilong Yang; Cong Zhang; Dawei Li; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  Biomed Res Int       Date:  2018-01-29       Impact factor: 3.411

4.  The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.

Authors:  Haifeng Song; Guanyu Kuang; Zhenan Zhang; Binglei Ma; Jie Jin; Qian Zhang
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

5.  Preoperative predictors of early death risk in bladder cancer patients treated with robot-assisted radical cystectomy.

Authors:  Zhaowei Zhu; Xiaojing Wang; Jiange Wang; Shengzheng Wang; Yafeng Fan; Tianlong Fu; Songqiang Cao; Xuepei Zhang
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

6.  Mex3a expression and survival analysis of bladder urothelial carcinoma.

Authors:  Jing-Wen Shi; Ying Huang
Journal:  Oncotarget       Date:  2017-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.